Daily Stock List
Elite Pharmaceuticals, Inc. (ELTP)
SmarTrend Newsletters, GoldminePennyStocks, Greenbackers, and PennyTrader Publisher reported on Elite Pharmaceuticals, Inc. (ELTP), and we highlight the Company, here at the QualityStocks Daily Newsletter.
Trading on the OTCBB, Elite Pharmaceuticals, Inc. is a specialty pharmaceutical enterprise. Their commitment is to developing and commercializing oral controlled release product formulations and the manufacturing of generic pharmaceuticals. The Company has four commercial products, with five additional products under review, pending approval by the Food and Drug Administration (FDA). Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, New Jersey.
Their strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Their lead pipeline products include abuse resistant opioids utilizing their patented proprietary technology, and a once-daily opioid. In addition, Elite Pharmaceuticals has partnered with Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the U.S. market and its territories.
For the fiscal year ended March 31, 2012, Elite incurred decreases in revenues and cash flows. These were the result of the removal of the Lodrane Extended Release products from the U.S. market, pursuant to a directive from the FDA which applied to approximately 500 products, including the Lodrane Extended Release Products. At the time of the FDA's directive, the Lodrane Extended Release Products comprised 97 percent of the Company's revenues.
Most of Elite's revenues during this fiscal year are the result of new products launched and new revenue streams created during fiscal 2012. The new products, all launched during this fiscal year, are phentermine tablets and hydromorphone tablets undergoing distribution under license by TAGI Pharma and Lodrane D® capsules co-developed and sold by ECR Pharmaceuticals. Elite also initiated contract manufacturing of methadone tablets for ThePharmaNetwork this fiscal year. Moreover, Elite now has two ANDAs pending approval with the FDA and two manufacturing transfers pending approval by the FDA.
This month, Elite Pharmaceuticals announced that they received approval, as of September 28, 2012, from the FDA for generic phentermine capsules 15 mg and 30 mg. They also announced that the sole supplier of the active pharmaceutical ingredient (API) approved for this phentermine capsule product has restricted the amount of API available to Elite and this will delay the launch of this product. The supply restriction also prevents Elite, and their sales and marketing partner, from meeting growing demand for the phentermine 37.5 mg tablets. The expectation is that the supply restriction will restrict sales of this product. Elite Pharmaceuticals believes the supplier is wrongfully limiting supply.
Elite Pharmaceuticals, Inc. (ELTP), closed Friday's trading session at $0.09, up 3.45%, on 303,622 volume with 34 trades. The average volume for the last 60 days is 763,679 and the stock's 52-week low/high is $0.067/$0.174.
EcoloCap Solutions, Inc. (ECOS)
OTCPicks, Wallstreetbuzz, Wall Street's Hottest, PennyTrader Publisher, HotShotStocks, and FeedBlitz reported earlier on EcoloCap Solutions, Inc. (ECOS), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
EcoloCap Solutions, Inc. concentrates on technology that utilizes advanced nanotechnology to design, develop, manufacture and sell alternative energy products. The Company is an integrated, environmentally focused technology enterprise. EcoloCap Solutions brings together the technology, engineering, and operational management for the successful development of environmentally significant products and projects. The Company lists on the OTCQB. EcoloCap Solutions has their headquarters in Barrington, Illinois.
The Company's products include Emulsified HFO (M-Fuel), Bio-Diesel from high fatty acid sources, old tires to syn-gas, diesel and charcoal, conversion of low-grade coal to syn-gas, methane and charcoal, and low emission conversion of Municipal Waste to steam.
EcoloCap Solutions, by way of their subsidiary Micro Bubble Technologies, Inc., developed and manufactures M-Fuel. This innovative suspension fuel significantly exceeds all conventional fuels' costs and efficiencies. M-Fuel is an environmentally friendly product designed to offer fully scalable and customizable fuel solutions that will increase efficiency, lower operating costs, and reduce emissions.
M -Fuel is a suspension mixture of 70 percent heavy oil, 28 percent water, and a 2 percent stabilizing additive. The production of M-Fuel takes place in EcoloCap's Nano Processing Units (NPUs), a self-contained device, sized for output. The NPUs can undergo configuration to operate in conjunction with an engine or burner to sully M-Fuel on demand, or pre-manufactured for delivery. The Company also offers a Glycerin Refining Process (GRP) that will refine glycerin to medical grade 99-plus percent.
Today, EcoloCap Solutions' CEO provided an update on recent activities. The Company is active on a number of fronts to actualize existing orders. In addition, they are progressing on several new opportunities for sales and financing.
Mr. Michael Siegel, President and CEO of EcoloCap, said, "I've been asked many times, how come the ECOS technology that has been proven to reduce diesel and other heavy oil consumption by up to 30 percent takes so much time to be totally accepted and implemented. We have also been struggling with that question in the past. Coming from other first movers and pioneers, the answer is that it takes more than a couple of years to move in the mainstream with a totally disruptive concept, a game changer. However, I want to report to our shareholders that we have paid our dues; we have taken the time and spent the money and energy to demonstrate our technology in many countries and almost every continent. We are very close to acceptance in many quarters and we are receiving new inquiries every week."
EcoloCap Solutions, Inc. (ECOS), closed Friday's session at $0.0142, up 18.33%, on 2,543,900 volume with 20 trades. The average volume for the last 60 days is 1,360,753 and the stock's 52-week low/high is $0.001/$0.0448.
Arctic Star Exploration Corp. (ADD.V)
Today we are highlighting Arctic Star Exploration Corp.(ADD.V), here at the QualityStocks Daily Newsletter.
Incorporated in 2001, Arctic Star Exploration Corp. is a junior natural resource company whose shares trade on the TSX Venture Exchange. The Company engages in the acquisition, exploration, and development of diamond and nickel properties in Canada. The Company was formerly known as Arctic Star Diamond Corp. They changed their name to Arctic Star Exploration Corp. in July 2011. The Company is based in Vancouver, British Columbia.
The Company's rare earths project in British Columbia is the CAP property. Arctic Star's three rare earth properties are in the Carbo area of northeastern British Columbia. The Cap, Seebach and Javorsky rare earth element (REE) and rare metal properties are all within the immediate vicinity of Spectrum Mining Corp.'s Wicheeda REE Discovery and the Carbo Project. The Carbo Project is currently undergoing drilling by Canadian International Minerals, Inc. CAP lies on the same geological belt approximately 50 km NE of Prince George within an emerging Alkaline-Carbonatite Rare Earth Element district. The Cap Property consists of five claims totaling 2,354 hectares.
In addition, the Company recently acquired a gold-copper exploration project called "El Havila", in Colombia, South America. The property shares the same geological belt as Ventana Gold's La Bodega project. Recent assays from a sampling program by Arctic Star at El Havila ran up to 19.3 g/t Gold on a grab sample. Arctic Star has an option to earn an 85 percent interest on the Property by making US$5,000,000 in exploration expenditures over a 3-year period. The Company's interest in the Property can be increased to 95 percent by the payment to the Property vendor of 15,246 troy ounces of gold. The Property vendor would retain a 5 percent free carried interest.
This past June, Arctic Star Exploration reported assays from their systematic outcrop channel sampling on the El Havila property, located near Frontino, Colombia. Of the 127 bedrock surface channel samples taken, 61 of the samples (48 percent), returned gold greater than 0.1g/t Au, 24 of the samples (18 percent) returned greater than 0.3g/t Au, 15 of the samples (11 percent) returned greater than 0.5g/t Au and 5 samples retuned greater than 1g/t. The highest-grade gold sample reported was 14.7g/t over one meter.
At the beginning of October, Arctic Star Exploration reported that they completed staking 10,000 ha of mineral claims in four separate claims in the Northwest Territories, north of Yellowknife. The claims are considered prospective for diamonds.
Arctic Star Exploration Corp. (ADD.V), closed Friday's trading session at $0.185, down 5.13%, on 68,333 volume. The stock's 52-week low/high is $0.12/$0.45.
Lustros, Inc. (LSLD)
UndiscoveredEquities reported this week on Lustros, Inc.(LSLD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Headquartered in California, Lustros, Inc. specializes in the production of Copper Sulfate from traditional mining and the treatment of copper tailings. In January of this year, Lustros purchased a majority stake of Sulfatos Chile SA., a Chilean private company currently involved in the manufacturing of Copper Sulfate and copper mining. Mineraltus SA, a subsidiary of Lustros, is in the process of implementing a new division specialized in the extraction of copper and other valuable minerals from tailings dumps. Lustros' manufacturing facilities are located in Chile, South America.
Lustros lists on the OTC Markets – OTCQB. The Company established in February of this year via a share exchange agreement between Power Save Energy Co. and Bluestone SA, a Chilean corporation. Because of this transaction, the Bluestone SA shareholders held approximately 96.7 percent of the Company's issued and outstanding common stock. In April 2012, the Company changed their name to Lustros, Inc. This was to reflect better the focus of the business following the acquisition of Bluestone SA.
In October 2012, Lustros announced the creation of Mineraltus Pudahuel Ltd. This single-purpose entity signed an agreement with Sociedad Mineral Pudahuel to process 2.4 million tons of copper-rich tailings from the La Africana mine located in the Santiago Metropolitan area. The project, known in the industry as the "Congo Project," has received all necessary approvals and permits from the Chilean authorities.
The Congo Project consists of 80.4 hectares of land in the Santiago Metropolitan Area currently affected by the tailings. Mineraltus will remove these tailings and restore the value of the property so that it can be used for real estate development projects. In return, Mineraltus will receive a track of land of 21.4 hectares next to the urban development, "Lomas De Lo Aguirre," presently valued at more than $10 million dollars.
Lustros' Sulfatos Chile S.A. owns the Anica Copper Mines and a copper sulfate production project. In 2011, Sulfatos Chile bought an 800-hectare property located in the Sierra del Cocou, Comuna de Illapel in the IV Region of Chile. The Company has dedicated 225 hectares to the construction of an industrial plant to process feed-grade Copper Sulfate. The assigning of the remaining area is for future growth and the development of additional plants. They will source the copper from the Company's Anica Mine, a 600-hectare mineral property located 15 miles from the plant.
Lustros, Inc. (LSLD), closed Friday's trading session at $1.38, up 6.15%, on 15,000 volume with 21 trades. The average volume for the last 60 days is 52,524 and the stock's 52-week low/high is $0.11/$2.48.
GrowLife, Inc. (PHOT)
OTCPicks reported recently on GrowLife, Inc. (PHOT), Penny Stock Pulse, PremiereStockAlerts, Street Beat, Orbit Stocks, Penny Stock Racer, Penny Stock Rumble, MyBestStockAlerts, Pumps and Dumps, Penny Stock Beats, Illuminati Stocks, Momentum Hunter, Cash Cow Stocks, OTC Showcase did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTCBB, GrowLife, Inc., formerly known as Phototron Holdings, Inc., has core holdings in creative technology-based products and services for the indoor gardening industry and specialty markets. GrowLife is a holding company for technology companies that make and market progressive grow technology products and life style products in the United States. The Company has their corporate headquarters in Woodland Hills, California.
The Company's Brands include Stealth Grow LED, producer of hi-powered LED grow light products for indoor horticulture (www.stealthgrow.com), Greners.com, the online hydroponics superstore (www.greners.com) and Phototron, producer of hydroponic grow containers, designed to grow vegetables, herbs, flowers and fruits in any environment (www.phototron.com).
GrowLife's companies also include SGSensors.com. They are an operating division of SG Technology that manufactures and markets wireless monitoring and control equipment to operate all major grow room functions. GrowLife also has their GrowLife Productions. This business unit's dedication is to the promotion of GrowLife's core brands via co-production and co-sponsorship of entertainment, lifestyle, music, and film events across the U.S.
In addition, the Company has their GrowLife Hydro, which owns and operates specialty hydroponics stores in Los Angeles (Southern California) and Cotai (Northern California). The Company also has their Cannabis.org. This is an information portal for the medical marijuana industry hosted and developed by GrowLife. Details pertaining to the creative content, celebrity-sponsor/contributors, as well as release plans will be announced in Q4 2012, closer to the full release of this web portal.
Yesterday, GrowLife announced the acquisition of Urban Garden Supplies, a retail hydroponics store with a significant presence in the Los Angeles market over the past 12 years. The stock transaction closed on October 22, 2012. This transaction furthers GrowLife's objective to build upon their presence in the retail hydroponics industry.
GrowLife CEO, Sterling Scott, said, "GrowLife's expansion into the retail hydroponics industry adds a key brick-and-mortar element to our digital strategy. After our recent acquisition of Greners.com, we've developed a leadership position in retail hydroponics online, while our new SG Sensor line has helped bolster our product line-up. The acquisition of Urban Garden Supplies marks our next step into the very profitable brick-and-mortar side of the business. Over the next couple of quarters, we will operate Urban Garden Supplies as a model store before exploring a nationwide rollout covering major population centers across the United States."
GrowLife, Inc. (PHOT), closed Friday's trading session at $0.04, up 5.26%, on 7,057,808 volume with 298 trades. The average volume for the last 60 days is 913,332 and the stock's 52-week low/high is $0.01/$0.25.
Com-Guard.com, Inc. (CGUD)
MicroCapDigest reported today on Com-Guard.com, Inc. (CGUD), Bull in Advantage, PennyStockLocks.com, StockLockandLoad, StockRockandRoll, StockBomb.com, Pumps and Dumps, Mega Stock Pick, Stocks Gone Wild did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.
Com-Guard.com, Inc. has been a developer in the security software market for more than ten years. The Company has been accepted as a developer for the fastest growing mobile platform iOSx, which includes the Apple iPhone™, iPod™ and iPad™. They currently sell two products related to security, DataCrypt™ and Missed Call Tracker.
Com-Guard.com lists on the OTC Pink Current Information. The Company was formerly known as e-World Security, Inc. They changed their name to Com-Guard.com, Inc. in April 1999. Incorporated on October 7, 1998 under the laws of the State of Nevada, the Company has their corporate headquarters in Encinitas, California.
Com-Guard.com will also acquire the tools for development on the Android platform from Google. The Company has published Apps on the iTunes store. They will explore new Apps and strategies to deliver Apps into the market. Com-Guard.com has licensed Software and Technologies in the past; they will continue to research and search for new products. Their current products are in the Security, Tracking, and the Utilities and Gaming categories. Future categories that they are exploring will include, but not be limited to, mobile medical Apps; location related Apps, as well as graphics/picture Apps.
The Company has distribution and licensing agreements for North America, including Canada, Mexico, and the Caribbean. Com-Guard.com licenses the aforementioned Missed Call Tracker software for loyalty programs. This is for tracking member activities and payments.
In September, Com-Guard.com announced that they would be focusing on applications for the Apple® iPhone 5. "The iPhone 5 ushers in new opportunities for software developers such as Com-Guard, Inc.," said Dr. Edward W. Savarese, Chief Executive Officer of Com-Guard.
In addition, in September, Com-Guard.com announced the hiring of Wall Street Branding, Inc. as their strategic consultant to help and assist in the acquisition and funding for the assorted upcoming projects that the Company is planning. Wall Street Branding is an internet and social networking enterprise that uses contemporary methods to build awareness throughout the internet.
Com-Guard.com, Inc. (CGUD), closed Friday's trading session at $0.004, up 2.56%, on 8,799,455 volume with 82 trades. The average volume for the last 60 days is 669627,493 and the stock's 52-week low/high is $0.0006/$0.0064.
Scientific Learning Corp. (SCIL)
SmarTrend Newsletters, MicroCap Press, SmallCapVoice, Wall Street Resources, OTC Picks, and Greenbackers reported earlier on Scientific Learning Corp. (SCIL), and we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Oakland, California, Scientific Learning Corp. provides education software to K-12 schools, educational institutions, speech and language clinics, and learning and tutorial centers around the world. Their science and technology-based solutions are available in over 40 countries. These are to help struggling readers accelerate their learning and reach their potential. Scientific Learning's shares trade on the OTC Markets –OTCQB.
Scientific Learning provides their offerings directly to parents, K-12 schools and learning centers. The Company accelerates learning through applying proven research on how the brain learns. The Company's results are demonstrated in more than 250 research studies and are protected by more than 55 patents. Learners can realize achievement gains of up to two years in as little as three months. They can maintain an accelerated rate of learning even after the programs end.
The Company's user-friendly, web-based products are powerful tools proven to accelerate learning in traditional, virtual, or blended learning settings. Their Fast ForWord® program is a reading intervention program designed for K-12 educational institutions and clinical specialists, whose students are struggling and reading below grade level. Additionally, Scientific Learning has their Reading Assistant™ web-based software. It acts as a personal, interactive reading tutor that provides real time, one-to-one guidance as students practice reading aloud.
Scientific Learning's Language and Literacy products build foundational reading and language skills to help districts move special needs learners to successful learners in the general classroom. Their Reading products increase processing efficiency and build critical reading skills in schools so districts get the most from their existing instructional approach. Furthermore, the Company has their Progress Tracker. An accountability tool, Progress Tracker provides complete visibility into individual, classroom, school, or district performance.
Earlier this month, Scientific Learning announced that the New Jersey Inventors Hall of Fame selected Scientific Learning co-founder Dr. Paula Tallal to receive an Inventor of the Year Award. A cognitive neuroscientist and board-certified clinical psychologist, Ms. Tallal will receive the award for her patented and innovative research leading to the creation of the Company's Fast ForWord® family of educational software products, which are used in school districts across New Jersey to accelerate learning for a broad spectrum of students.
Scientific Learning Corp. (SCIL), closed Friday's session at $0.72, up 2.86%, on 51,600 volume. The average volume for the last 60 days is 5,555 and the stock's 52-week low/high is $0.44/$3.49.
Creative Edge Nutrition, Inc. (FITX)
Fast Moving Stocks, Penny Stocks Profile, Stock Exploder, and Stock Mister reported this month on Creative Edge Nutrition, Inc. (FITX), and we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Creative Edge Nutrition, Inc. is a holding company and a Nutritional Supplement Company whose shares trade on the OTC Pink Current Information. The Company focuses on developing innovative, high quality supplements. They manufacture under strict GMP guidelines at GMP Certified and/or FDA registered facilities. Creative Edge Nutrition is headquartered in Madison Heights, Michigan.
The Company offers a wide array of capsules, tablets, and powders, as well as science based products. They offer these in the principal categories of weight management, nutrition challenges, energy and fitness. Their products are scientifically designed and formulated to enhance athletic performance and well-being. The products are manufactured in the United States.
One of Creative Edge Nutrition's products is MetaBolic Xtreme™. MetaBolic Xtreme™ uses the latest technology and advancement in weight loss technology. It increases metabolic rate and energy levels. It also controls appetite urges, promoting weight loss while sparing muscle. The Company also offers their Cenergy Amino Acid Complex™. This is a supplement for athletes, bodybuilders, and anyone who is trying to live a healthy lifestyle. Amino acids help the body recover from workouts and the stresses of every day living.
Furthermore, Creative Edge Nutrition offers their Cenergy Vaso-Bolic™. This product induces cell volumization, nitric oxide production, and maximizes vascularity. Additionally the Company has their Cenergy Apparel. This apparel is for lifting, running, hiking, climbing, biking or playing ball.
In late September, Creative Edge Nutrition announced details of the completed acquisition of Sci-Fit (www.scifitauthentic.com) and Nature's Science product brands. Sci-Fit and Nature's Science debuted in 1997. They grew to a combined 600 product SKU's sold in the U.S. and 20 foreign markets.
This month, Creative Edge Nutrition announced the details and name of the acquisition of Chesapeake Nutraceuticals (www.chesapeakenutraceuticals.com
) from the August 20, 2012 press release. Chesapeake Nutraceuticals was a wholly owned subsidiary of SCD Enterprises, a vertically integrated nutritional supplement holding company. Chesapeake Nutraceuticals provides premium grade supplements to aging Americans. Their products are formulated in conjunction with the latest research from elite U.S. and International Medical Institutions.
Creative Edge Nutrition, Inc. (FITX), closed Friday's trading at $0.008, up 9.59%, on 136,600 volume with 10 trades. The average volume for the last 60 days is 2,364,728 and the stock's 52-week low/high is $0.0013/$0.0398.
TNI BioTech, Inc. (TNIB)
The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $4.20, up 7.69%, on 27,172 volume with 44 trades. The stock’s average daily volume over the past 60 days is 42,108, and its 52-week low/high is $0.72/$10.01.
TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.
The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.
Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.
The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer
TNI BioTech, Inc. Company Blog
TNI BioTech, Inc. News:
TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies
Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer
TNI BioTech Signs Agreement With Government of Malawi to Open an Oncology & Infectious Disease Clinic at Queen Elizabeth Central Hospital
GreeneStone Healthcare Corp. (GRST)
The QualityStocks Daily Newsletter would like to spotlight GreeneStone Healthcare Corp. (GRST). Today, GreeneStone Healthcare Corp. closed trading at $1.60, up 3.23%, on 2,232 volume with 7 trades. The stock’s average daily volume over the past 60 days is 16,814, and its 52-week low/high is $0.70/$1.83.
GreeneStone Healthcare Corp. (GRST) is focused on operating medical and healthcare clinics in Ontario, Canada, offering addiction treatment, colonoscopy, endoscopy, minor cosmetic procedures, and executive health assessment programs. The company adds overflow capacity to an increasingly stretched provincial healthcare system, and provides private alternatives to publicly underserviced healthcare needs.
Ontario's public healthcare cost has grown at a compounded 7.1% rate over the past 10 years, now accounting for approximately $77B in government spending compared to $39B in 2000. This cost explosion is similar for the country as a whole, growing at 7.4% over the same period. The need for practical change to the system is immediate as demand continues to rise.
Governments are increasingly looking to private alternatives to address the growing trade-off between costs vs. service in the public healthcare system. Private services are expanding beyond their traditional place as overflow capacity to relieve wait times. GreeneStone Healthcare is particularly well positioned with a first-mover advantage in mental healthcare – a highly underserviced niche.
The company currently offers its various medical services via three medical clinics. Future plans include establishing partnerships for accelerated growth as well as dual-listing on CNSX. With positive revenue growth and cash flow positive status recently achieved, GreeneStone is methodically extending its vertical expertise in the healthcare industry. Disclaimer
GreeneStone Healthcare Corp. Company Blog
GreeneStone Healthcare Corp. News:
GreeneStone Implementing 'Build & Buy' Growth Strategy To Capitalize On Huge Opportunity In Behavioral Treatment
GreeneStone Supports the Cause of Mental Health with Charitable Foundation
GreeneStone Muskoka Once Again Featured on Intervention Canada
Cardium Therapeutics, Inc. (CXM)
The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.1965, up 3.10%, on 191,512 volume with 54 trades. The stock’s average daily volume over the past 60 days is 266,868, and its 52-week low/high is $0.1771/$0.47.
Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.
The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer
Cardium Therapeutics, Inc. Company Blog
Cardium Therapeutics, Inc. News:
DUMA - Duma Energy Corp, Zacks Initiating Coverage
Duma Energy Corp. Partners with Hydrocarb to Explore for World Class Reserves in Africa Oil Concession
Duma Energy Receives Approval From Government of Namibia for Exploration License Issued for 5.3 Million-Acre Concession
Loans4Less.com, Inc. (LFLS)
The QualityStocks Daily Newsletter would like to spotlight Loans4Less.com, Inc. (LFLS). Today, Loans4Less.com, Inc. closed trading at $0.075, even for the day. The stock’s average daily volume over the past 60 days is 9,932, and its 52-week low/high is $0.01/$0.51.
Loans4Less.com, Inc. (LFLS) is an online mortgage broker which matches qualified individuals seeking mortgage loans with suitable lenders who offer the company a competitive wholesale lending program. Maintaining an A+ TrustLink rating with the Better Business Bureau, the company provides competitive rates, terms, costs, daily updates, extensive market information, and trusted first-class service to the public.
Leveraging its portfolio of 62 different web domains, Loans4Less.com is focused on developing a national consumer platform for conforming residential mortgage programs and implementation of other consumer loan programs via operating providers. The company's expansion strategy includes rapidly growing revenues through strategic and cost-effective advertising, licensing, and/or third party agreements that build national recognition of the Loans4Less® brand.
The management team has accumulated many years of experience in the real estate and financial services sectors. This combination of expertise provides the knowledge and foresight necessary to get the best results for the company and their thousands of loyal clients. The team skillfully navigated through the credit crisis that destroyed much of their competition, putting the company in a stronger position to increase market share.
Loans4Less.com is not exposed to the risks and/or problems that are associated with sub-prime lending. Having never defaulting on an obligation or been involved in any litigation, the company is poised for rapid growth in today's low interest rate environment with its industry leading reputation and well established relationships with respected lenders. Disclaimer
Loans4Less.com, Inc. Company Blog
Loans4Less.com, Inc. News:
Loans4Less.com Provides Preliminary Financial Results for the Third Quarter of 2012
Loans4Less.com, Inc. New Audio Interview With Chairman and CEO Steven M. Hershman
Loans4Less.com, Inc. Announces Engagement of QualityStocks Investor Relations Services.
TNI BioTech’s announcement that it will partner with leading Chinese pharmaceutical company Hubei Qianjiang Pharmaceutical in developing anti-cancer drugs for marketing in China is the latest confirmation of the company’s intended long-term international orientation. Citizens of industrialized countries like the U.S. generally have more access to intensive and costly high-tech medicines and treatment options than in other parts of the world. It’s a situation that represents new potential markets for developers of alternative drugs. In addition, such markets can also represent financial and other resources for faster development, approval, production, and marketing of new drugs.
In the case of the China deal, Hubei Qianjiang Pharmaceutical will provide $1.6 million for pre-clinical work in developing TNI’s IRT-101 and IRT-102 immunotherapy drugs, in addition to offering a solid link to the intricacies of the Chinese drug market. After completion of the pre-clinical studies, Hubei will provide the funding for clinical trials in China to have Methionine Enkephalin approved as a new drug for the treatment of cancer.
Earlier, TNI announced an agreement to open an outpatient clinic in Malawi, Africa, for the treatment of cancer and infectious diseases, in conjunction with GB Oncology & Imaging Group. Infection-related cancers are especially problematic in people infected with HIV, which is a major factor in Malawi. Cancer patient survival rates in the country are very low due to a lack of early diagnosis and treatment.
TNI also recently announced the building of a new pharmaceutical plant in South America. The plant, located in Managua, Nicaragua, will produce the company’s IRT-103 active immunotherapy drug for use against HIV/AIDS and tumor cells. In a unique arrangement, two of the owners of Pharmaceutical Care Consultants of South Florida, the leading outlet for the supply of IRT-103 (LDN) for over ten years, have agreed to head up the QC and QA aspects of the new plant.
For more information, visit www.tnibiotech.com
Loans4Less.com, as a Web-dedicated mortgage broker currently focused primarily on the massive California residential marketplace, must have its feet planted firmly in two related but individual industries: finance and real estate. With the financial and housing earthquake that the nation recently experienced, this has required an operational team that is well-versed in the changing market and regulatory aspects of both.
• Steven Hershman (Chairman, President, Treasurer, and CFO) has devoted much of his professional life to the development of Loans4Less and its above-board and transparent approach to the mortgage market. A citizen of the United States and the UK, he holds a California Real Estate Broker License, but started his career on the London Stock Exchange in 1977 where he became a Member of The London Stock Exchange in 1981. Between 1982 and 1990 he worked for Thomson McKinnon Securities, Inc. and Ladenburg, Thalmann Members of The New York Stock Exchange. Then, in 1990, he became a mortgage broker, forming, in 1993, Union Discount Mortgage, Inc.
• Julia Greenfield, Attorney-At-Law (Director, Secretary) has been a practicing attorney since 1976, representing several major savings banks and mortgage lenders, and specializing in mortgage banking laws with an emphasis on origination, servicing, secondary market whole-loan sales, securitization of prime and subprime residential mortgage loans, Truth-In-Lending and regulatory compliance under federal and state law. She is a member of the State Bar of Pennsylvania, State Bar of California, and American Bar Association. She received her Juris Doctorate in May 1976 from Villanova University School of Law, and her Bachelor of Arts (Phi Beta Kappa) in 1973 from the State University of New York at Binghamton.
• Martin Genis (Director, Executive VP) has been involved since 1997 in the development of the company’s real estate division, Platinum Properties. Since 1990, Mr. Genis has been licensed with the California Department of Real Estate and has been employed as a realty agent specializing in residential listings and purchases with the Jon Douglas Company, Los Angeles.
• Daniela Haynie (Director, Executive VP) serves as the company’s underwriting manager and mortgage loan processor, assisting in the processing and closing of mortgage loan transactions, and has worked with the company since 2001. From 1997 to 2001, she served as a mortgage loan underwriter, assisting brokers and various loan officers in processing and closing mortgage loan transactions for Crestwood Mortgage Company, Torrance, California. She graduated from the University of Sao Judas Tadeu (Sao Paulo, Brazil) in 1995, moving to the U.S. in 1996.
• Marc Phelps, CPA (Director) has been in public accounting since 1982, assisting small businesses with their accounting systems and business management. Since 1999 he has also helped small businesses with the audit process, both as the auditor and as a consultant assisting small companies to get ready for audits. He is a CPA, licensed to practice in the State of California. In 1999, he received a Bachelor of Science degree in Business Administration (Magna Cum Laude) from California State University Dominquez Hills.
For more information, visit www.Loans4Less.com
Ramius LLC, the worldwide alternative investment management business of Cowen Group, has announced that the Ramius Trading Strategies Managed Futures Fund (Ticker: RTSIX, RTSRX) has been added to the recommended list of mutual fund products on Fortigent LLC’s alternatives platform. Fortigent is a leader in providing high-net-worth solutions and consulting services to RIAs, banks, and trust companies.
Ramius was selected after a rigorous due diligence process. Being chosen as one of the recommended mutual funds for Fortigent’s rapidly growing platform is evidence of Fortigent’s confidence and trust in Ramius’ products and services. Ramius will now have the opportunity to offer liquid alternatives – which are fast becoming an important investment option for investors to diversify their portfolios – on Fortigent’s highly selective platform.
Ramius recently published a detailed view of the liquid alternative investment space with a focus on managed futures investing. This white paper can be accessed at http://goo.gl/wMpDE.
Founded in 2009, Ramius Trading Strategies (RTS) is an affiliate of Cowen Group, Inc. and Ramius Alternative Solutions LLC. RTS provides multimanager products investing in independent managers in the managed futures and global macro space. All RTS products utilize RTS’ managed account platform, supported by RTS’ proprietary risk and research systems as well as the operational infrastructure of Ramius.
Grand Distribution Services LLC distributes Ramius Alternative Strategy Mutual Funds.
Ramius is the global alternative investment management business of Cowen Group, offering a wide range of investment solutions to institutions and private clients throughout the world. Cowen Group is a diversified financial services firm. Together with its consolidated subsidiaries, Cowen Group provides alternative investment management, investment banking, research, and sales and trading services through Ramius and affiliates, the company’s alternative investment management segment, and Cowen and Company, its broker-dealer segment. The company’s alternative investment management products, solutions, and services include hedge funds, replication products, managed futures funds, fund of funds, real estate, healthcare royalty funds, and cash management services. Cowen and Company offers industry-focused investment banking for growth-oriented companies, domain knowledge-driven research, and a sales and trading platform for institutional investors. The firm was founded in 1918 and is headquartered in New York, with offices located in major financial centers across the globe.
For more information, visit the company’s Web site at www.cowen.com
RTI Biologics, a processor of orthopedic, dental, surgical specialties, and other biologic implants, today announced the launch of an innovative, new biologic implant for use in sports medicine, orthopedic, and pine surgeries. BioReady™ DBM Putty and Putty with Chips is an instant use, 100 percent allograft DBM product. BioReady DBM putty is included in RTI’s DBM portfolio, which already features BioSet™ DBM Paste and BioAdapt™ Foam.
BioReady DBM Putty is a ready-to-use demineralized bone matrix (DBM) implant that provides convenience, robust handling, verified osteoinductive* potential, and sterility. It was introduced at the RTI Biologics exhibit at the North American Spine Society (NASS) annual meeting in Dallas this week.
BioReady DBM Putty and Putty with Chips are 100 percent allograft, and each donor lot is tested for osteoinductive potential. Data shows that BioReady DBM Putty retains its osteoinductive potential throughout its entire shelf life. This ready-to-use implant does not require any preparation, such as thawing or mixing, and it is available in various sizes for use as a bone void filler in many types of surgical procedures.
“BioReady is an exciting allograft solution that complements our portfolio of DBM implants including BioSet and BioAdapt,” said Roger Rose, executive vice president and chief commercial officer for RTI Biologics. “This ready-to-use implant addresses a significant clinical need and ensures that we maximize every gift of donation received.”
All of RTI’s implants go through a sterilization process validated by tissue type. The sterilization process used for BioReady DBM Putty is known as the Cancelle™ SP Demineralization Process. It uses a mixture of oxidative treatments and acid or alcohol washes to remove cellular debris and deactivate pathogens. Subsequent cleansing rinses serve to remove residual chemicals, maintaining biocompatibility.
For further information, please visit www.rtix.com
Today's Top 3
Center Stage Stocks
Wall Street Resources
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Cardium Therapeutics, Inc. (CXM) Announces the Acquisition of To Go Brands
- Consorteum Holdings, Inc. (CSRH) Subsidiary, Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming with the Acquisition of To Go Brands
- GlobalWise Investments, Inc. (GWIV) Announces New Channel Partnership With Level Seven
- GreeneStone Healthcare Corp. (GRST) Implementing 'Build & Buy' Growth Strategy To Capitalize On Huge Opportunity In Behavioral Treatment
- International Stem Cell Corp. (ISCO) Discusses Its New Cellular Reprogramming Technology in View of the Recent Award of the Nobel Prize in Physiology or Medicine
- Loans4Less.com, Inc. (LFLS) New Audio Interview With Mr. Steven M. Hershman, Chairman and CEO via SmallCapVoice
- Skinny Nutritional Corp. (SKNY) to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+
- Teletouch Communications, Inc. (TLLE) Returns as Official Cellular Sponsor for the 10th Anniversary ESPN 2012 Bell Helicopter Armed Forces Bowl
- TNI BioTech Inc. (TNIB) Dr. Henry "Skip" Lenz, Pharm.D, Joins the Company as Quality Control Officer
- VistaGen Therapeutics, Inc. (VSTA) Announces Strategic Financing With Platinum Long Term Growth Fund